Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

OX40: a win–win path to tumor immunity

OX40: a win–win path to tumor immunity <h2>OX40: a win–win path to tumor immunity</h2> Mice injected with agonist anti-OX40 antibody remain tumor-free after injection with cancer cells. Regulatory T (T reg) cells prevent autoimmunity by keeping self-reactive effector T cells in check, but this suppression becomes counterproductive when the effector cells are prevented from attacking tumors. Piconese et al. now show on page 825 , however, that tumor immunity can be achieved without risking autoimmunity simply by stimulating a T cell surface protein called OX40. A major challenge in tumor immunotherapy lies in breaking T reg cell–mediated tumor tolerance without inducing organism-wide autoimmunity or compromising immune surveillance. This goal has remained elusive because current methods used to derail T reg cell activity—such as depleting them using antibodies to a major T reg cell surface marker, CD25—also target effector T cells, thereby preventing tumor immunity and perhaps immunity to pathogens. T reg cell depletion also provokes conversion of effector T cells into T reg cells, thus worsening the initial immune suppression. Piconese et al. sought a different approach by targeting OX40 because its stimulation suppresses T reg cell function while enhancing effector T cell survival and activity in vitro. Mice injected with agonistic anti-OX40 antibody before http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Experimental Medicine Rockefeller University Press

OX40: a win–win path to tumor immunity

Sedwick, Caitlin
The Journal of Experimental Medicine , Volume 205 (4): 742 – Apr 14, 2008
Download PDF
2 pages

Loading next page...
 
/lp/rockefeller-university-press/ox40-a-win-win-path-to-tumor-immunity-vxc1injlTW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Rockefeller University Press
Copyright
© 2008 Rockefeller University Press
ISSN
0022-1007
eISSN
1540-9538
DOI
10.1084/jem.2054iti2
Publisher site
See Article on Publisher Site

Abstract

<h2>OX40: a win–win path to tumor immunity</h2> Mice injected with agonist anti-OX40 antibody remain tumor-free after injection with cancer cells. Regulatory T (T reg) cells prevent autoimmunity by keeping self-reactive effector T cells in check, but this suppression becomes counterproductive when the effector cells are prevented from attacking tumors. Piconese et al. now show on page 825 , however, that tumor immunity can be achieved without risking autoimmunity simply by stimulating a T cell surface protein called OX40. A major challenge in tumor immunotherapy lies in breaking T reg cell–mediated tumor tolerance without inducing organism-wide autoimmunity or compromising immune surveillance. This goal has remained elusive because current methods used to derail T reg cell activity—such as depleting them using antibodies to a major T reg cell surface marker, CD25—also target effector T cells, thereby preventing tumor immunity and perhaps immunity to pathogens. T reg cell depletion also provokes conversion of effector T cells into T reg cells, thus worsening the initial immune suppression. Piconese et al. sought a different approach by targeting OX40 because its stimulation suppresses T reg cell function while enhancing effector T cell survival and activity in vitro. Mice injected with agonistic anti-OX40 antibody before

Journal

The Journal of Experimental Medicine – Rockefeller University Press

Published: Apr 14, 2008

There are no references for this article.